|Home | About | Journals | Submit | Contact Us | Français|
The mechanisms involved in the coordinate regulation of the metabolic and structural programs controlling muscle fitness and endurance are unknown. Recently, the nuclear receptor PPARβ/δ was shown to activate muscle endurance programs in transgenic mice. In contrast, muscle-specific transgenic overexpression of the related nuclear receptor, PPARα, results in reduced capacity for endurance exercise. We took advantage of the divergent actions of PPARβ/δ and PPARα to explore the downstream regulatory circuitry that orchestrates the programs linking muscle fiber type with energy metabolism. Our results indicate that, in addition to the well-established role in transcriptional control of muscle metabolic genes, PPARβ/δ and PPARα participate in programs that exert opposing actions upon the type I fiber program through a distinct muscle microRNA (miRNA) network, dependent on the actions of another nuclear receptor, estrogen-related receptor γ (ERRγ). Gain-of-function and loss-of-function strategies in mice, together with assessment of muscle biopsies from humans, demonstrated that type I muscle fiber proportion is increased via the stimulatory actions of ERRγ on the expression of miR-499 and miR-208b. This nuclear receptor/miRNA regulatory circuit shows promise for the identification of therapeutic targets aimed at maintaining muscle fitness in a variety of chronic disease states, such as obesity, skeletal myopathies, and heart failure.
Muscle fitness is an important determinant of health and disease. Muscle endurance, strength, and fatigability are determined by a variety of factors, including delivery of substrate for ATP production, mitochondrial capacity to burn fuels, and composition of the contractile machinery (1–3). Although genetic factors serve to determine the fundamental muscle phenotype, physiological factors such as physical activity and exercise also contribute during the postnatal period through effects on fiber-type composition, mitochondrial biogenesis, and energy metabolic pathways.
Muscle fibers can be broadly classified as slow twitch (type I) and fast twitch (type II). Type I fibers are mitochondria-rich, relying largely on mitochondrial fatty acid oxidation for ATP production. Type II fibers rely on glucose as an energy substrate and are subclassified as type IIa, IIx, or IIb in rodents based on the type of myosin heavy chain (MHC) isoform expressed (4, 5). Whole-body insulin sensitivity and insulin-stimulated glucose transport are positively correlated with the proportion of type I muscle fibers (6–9). Endurance exercise training increases the proportion of oxidative fibers in parallel with a mitochondrial biogenic response, which, in turn, increases capacity for exercise, oxidation of fatty acids and glucose, and energy expenditure (1–3, 10). Conversely, reduced physical activity, such as occurs in obese states and chronic illness, results in a reduction in the proportion of type I and IIa fibers, along with reduced muscle glucose disposal and insulin sensitivity (11, 12).
The mechanisms involved in the coordinate regulation of the metabolic and structural determinants of muscle fitness and endurance during development and in response to physiological stimuli are unknown. Recent studies in muscle-specific transgenic mice have provided important clues. Mice overexpressing the transcriptional coactivator PGC-1α exhibit increased muscle mitochondrial density and respiratory capacity, a greater proportion of oxidative muscle fibers, and enhanced exercise performance (13). Muscle-specific transgenes for the nuclear receptor PPARβ/δ also exhibit a “trained” phenotype, in which both energy metabolic and fiber-type programs linked to muscle endurance are activated, in the absence of exercise (14–16). In contrast, we recently found that muscle-specific transgenic overexpression of a related nuclear receptor, PPARα (MCK-PPARα mice), results in reduced endurance (16, 17).
The strikingly different muscle phenotypes of PPARα and PPARβ/δ transgenic mice suggested that the circuitry involved in the control of muscle endurance is differentially regulated in the two lines. We took advantage of the divergent actions of PPARβ/δ and PPARα in muscle to explore the downstream regulatory circuitry that coordinately regulates muscle fiber type and energy metabolism (16). We found that, in addition to the well-established role in the transcriptional control of energy metabolic genes, PPARβ/δ and PPARα participate in programs that exert opposing actions upon the slow-twitch type I fiber program through a distinct muscle microRNA (miRNA) network. Our studies also strongly suggest that the estrogen-related receptor γ/miRNA (ERRγ/miRNA) circuitry is operational in human muscle.
The distinct exercise phenotypes of the two MCK-PPAR lines (16) afforded us the opportunity to use a comparative molecular profiling strategy to identify gene regulatory networks involved in the coordinate control of muscle energy metabolism and fiber type. Muscle phenotyping and transcriptional profiling revealed that fiber-type programs are differentially regulated, at the gene regulatory level, in the MCK-PPAR lines; expression of type I genes is increased in MCK-PPARβ/δ muscle but is decreased in MCK-PPARα muscle (Supplemental Table 1; supplemental material available online with this article; doi: 10.1172/JCI67652DS1). Gene expression validation studies demonstrated that the expression of the gene encoding the major slow-twitch type I myosin isoform MHC1 (Myh7 gene) and slow-twitch troponin genes was increased in MCK-PPARβ/δ soleus muscle, concomitant with a reduction in the expression of the MHC2a (Myh2), MHC2x (Myh1), and MHC2b (Myh4) genes (Figure (Figure1A1A and data not shown). In striking contrast, expression of Myh7 and slow-twitch troponin genes was reduced in MCK-PPARα soleus muscle (Figure (Figure1A).1A). Similar observations were made in gastrocnemius (GC) muscles of the MCK-PPAR lines (Supplemental Figure 1, A and B). Consistent with the gene expression results, metachromatic ATPase and MHC immunostaining demonstrated an increase in MHC1-positive (type I) fibers in MCK-PPARβ/δ muscle but a marked reduction of MHC1-positive fibers in MCK-PPARα muscle (Figure (Figure1,1, B and C). These results were not due to differences in spontaneous locomotor activity, muscle size, or fiber density of the MCK-PPAR lines compared with nontransgenic (NTG) littermate controls (data not shown).
Loss-of-function experiments were conducted to determine whether PPAR signaling is required for normal muscle fiber-type programming. MHC1-positive muscle fibers were significantly increased, together with elevated expression of slow-twitch troponin genes, in GC muscles of PPARα-null mice compared with those in controls (Figure (Figure1,1, D and E). However, type I fiber proportion was normal in PPARα-null soleus (data not shown), suggesting the existence of redundant pathways in this muscle. In vitro manipulation of PPARα or PPARβ/δ levels in a primary skeletal myocyte culture system further demonstrated that the two nuclear receptors exert opposing effects on Myh7 expression (Figure (Figure1F1F and Supplemental Figure 2, A and B). Taken together, these data demonstrate essential and opposing roles of PPARβ/δ and PPARα in the regulation of type I muscle fiber type.
Evidence is emerging that coordinate modulation of gene regulatory circuits is often directed by miRNAs (18). Therefore, unbiased muscle miRNA profiling was conducted, unveiling interesting differences between the MCK-PPAR lines (Supplemental Figure 3). Two miRNAs implicated previously in muscle fiber-type programs (19) were differentially regulated: miR-208b, which is encoded within the Myh7 gene, and miR-499, which is encoded within the Myh7b gene. miR-499 and miR-208b, which target the same mRNA targets, have been shown to drive a slow-twitch program by downregulating transcriptional repressors of slow-twitch contractile protein genes, such as Sox6 (19, 20). Expression of miR-208b was significantly increased in MCK-PPARβ/δ muscle but was undetectable in MCK-PPARα muscle (Figure (Figure2A2A and Supplemental Figure 3). In addition, miR-499 expression was increased in MCK-PPARβ/δ muscle but dramatically reduced in MCK-PPARα muscle (Figure (Figure2B2B and Supplemental Figure 3). Similar results were obtained in skeletal myocytes in culture, using either transgenic cells or adenoviral-mediated PPAR overexpression in WT myocytes (Figure (Figure2C,2C, top). Furthermore, miR-208b and miR-499 levels were increased in PPARα-null GC muscle and cultured myocytes (Figure (Figure2D,2D, top, and data not shown), whereas shRNA-mediated knockdown (KD) of PPARβ/δ in WT myotubes reduced levels of miR-208b and miR-499 (Figure (Figure2D,2D, top). As expected, the expression of the Myh7 and Myh7b genes paralleled the levels of miR-208b and miR-499, respectively, in these studies (Figure (Figure22).
We next assessed the effects of manipulating miR-208b and miR-499 levels on the PPAR-mediated control of slow fiber type. First, the impact of antisense-mediated inhibition of miR-208b and/or miR-499 on MHC gene expression was evaluated in MCK-PPARβ/δ and NTG myotubes. Whereas inhibition of either miR-208b or miR-499 alone had no effect on MHC expression, inhibition of both miRNAs resulted in a significant decrease in Myh7 mRNA in WT myotubes and abolished the enhancing effects of PPARβ/δ on slow-twitch gene expression in MCK-PPARβ/δ myotubes (Figure (Figure3A).3A). Second, to assess the relevance of this pathway in vivo, muscle-specific miR-499 transgenic mice (MCK-miR-499 mice) were bred with the MCK-PPARα line. The resultant cross prevented the PPARα-mediated repression of the type I muscle fiber-type program (Figure (Figure3,3, B–D) and reversed the exercise performance deficit of the MCK-PPARα mice (Figure (Figure3E).3E). Taken together, these results support a model in which PPAR signaling is upstream of miR-208b/miR-499 and that PPARβ/δ activates, whereas PPARα suppresses, Myh7/miR-208b and Myh7b/miR-499 expression in muscle.
We next sought to determine the mechanism whereby the Myh7/miR-208b and Myh7b/miR-499 transcripts were upregulated in the MCK-PPARβ/δ line. Analysis of the Myh7/miR-208b and Myh7b/miR-499 promoter regions did not reveal consensus PPAR binding sites. However, highly conserved sequences that conformed to the consensus binding sites for ERR were identified in both promoter regions (Figure (Figure4A).4A). The putative Myh7 ERR binding site is located well upstream of the well-described proximal promoter elements known to respond to the thyroid receptor, MCAT, and Sox6 (20, 21). Notably, ERRγ has been shown recently to activate oxidative muscle fiber programs in a manner similar to that of PPARβ/δ (14, 22). We found that ERRγ (Esrrg) mRNA and protein levels were increased in MCK-PPARβ/δ muscle but not in MCK-PPARα muscle (Figure (Figure4B4B and data not shown). ERRβ (Esrrb), but not ERRα (Esrra), expression was also increased in MCK-PPARβ/δ muscle (Figure (Figure4B).4B). In contrast, the expression of the genes encoding PGC-1α and PGC-1β, known activators of muscle endurance, was not increased in MCK-PPARβ/δ muscle compared with that in controls (Supplemental Figure 4A). siRNA-mediated KD of ERRγ attenuated the PPARβ/δ-mediated activation of Myh7 and Myh7b transcript levels (Figure (Figure4C).4C). In addition, ERRγ and ERRβ activated a 1-kb mouse Myh7b promoter-reporter via the ERR site in C2C12 myotubes (Figure (Figure4D).4D). Interestingly, PGC-1α, when overexpressed in cells, did not have a coactivating effect on ERRγ, using the Myh7b promoter-reporter as a readout (Supplemental Figure 4B). ChIP studies confirmed that ERRγ occupies the regions of the Myh7 and Myh7b promoters containing the ERR-responsive elements (Figure (Figure4E).4E). In addition, ERRγ occupied a putative regulatory region (based on ENCODE/LICR data in the UCSC Genome Browser) containing multiple conserved ERR response elements, approximately 10 kb upstream of the Myh7 gene transcription initiation site (Figure (Figure4E).4E). Interestingly, these sites are markedly stronger than a previously identified ERR element (20077 bp downstream of the Myh7 transcription start site) in heart (23).
To assess the role of ERR signaling in the miR-499/miR-208b–mediated control of muscle fiber type in vivo, mice with skeletal muscle–specific disruption of the Esrrg and Esrrb genes (ERRβ/γ dmKO mice) were generated and analyzed (Supplemental Figure 5). Levels of miR-499 and miR-208b were dramatically reduced in ERRβ/γ dmKO GC muscle (Figure (Figure5A).5A). In addition, slow-twitch fiber gene expression and MHC1-positive fibers were reduced in ERRβ/γ dmKO GC muscle (Figure (Figure5,5, B–D). These results were not due to differences in the general spontaneous activity of the mice or obvious pathologic changes in the muscles of the ERRβ/γ dmKO line. Interestingly, a change in type I fiber composition was not observed in the soleus muscles of the ERRβ/γ dmKO mice (data not shown), suggesting the existence of additional converging pathways involved in the control of fiber type in this muscle.
We next assessed acute running endurance performance in the ERRβ/γ dmKO line using a run-to-exhaustion protocol on a motorized treadmill. Consistent with the observed alterations in muscle fiber-type proportion, the ERRβ/γ dmKO mice achieved a shorter distance compared with that of the WT controls (Figure (Figure55E).
To define the mechanism by which PPARα downregulates miR-208b and miR-499 gene expression, transcriptional regulation studies were conducted by transiently transfecting rat 3.5-kb Myh7 and mouse 1.0-kb Myh7b promoter-reporter constructs into C2C12 myotubes. In agreement with the RNA quantification data, cotransfection of PPARα suppressed both promoters (Supplemental Figure 6A). Interestingly, this effect occurred independently of exogenously added PPARα ligand. A series of deletion mapping studies was used to demonstrate that PPARα suppresses Myh7/miR-208b promoter activity through a region within 408 bp upstream of the transcription initiation site (downstream of the identified ERR site) (Supplemental Figure 6B). In addition, the PPARα-mediated repression was maintained in a Myh7b gene promoter-reporter in which the ERR-responsive element was mutated (Supplemental Figure 6C). Taken together, these results strongly suggest that PPARα suppresses Myh7/miR-208b and Myh7b/miR-499 promoter activity independent of the ERR-responsive element. Given that the responsive region does not contain a classic PPAR DNA recognition site, it is likely that this repressive effect occurs via indirect mechanisms, possibly via other transcription factors occupying this region.
We next sought to determine whether this program can be activated by stimuli known to induce muscle type I fiber programs. Chronic low-frequency electrical stimulation (CLFS) of myotubes in culture has been shown to increase slow myosin gene expression and enhance contractile properties of muscle cells in culture (24–26). Therefore, we conducted experiments to determine whether the ERRγ/miRNA circuit is activated in response to CLFS in WT mouse primary skeletal myotubes. CLFS for 4 days induced an increase in proportion of type I fibers (Figure (Figure6A)6A) and expression of Myh7, Myh7b, miR-499, and miR-208b (Figure (Figure6B).6B). In contrast, the fast fiber-type gene Myh4 was not induced by CLFS (data not shown). Esrrg levels, but not PPARβ/δ levels (data not shown), were also induced by CLFS (Figure (Figure6B).6B). Importantly, KD of ERRγ abolished the CLFS-mediated increase in Myh7, Myh7b, miR-499, and miR-208b (Figure (Figure6B).6B). These results further support the importance of the ERRγ/miRNA axis in type I fiber-type expression and demonstrate that it is an inducible program.
To determine the relevance of the ERRγ/miRNA circuit in humans, muscle biopsies from 8 active, trained (referred to herein as “active”) individuals and 17 healthy sedentary controls were analyzed. Previous analyses demonstrated that the biopsy specimens from the “active” group contain a higher percentage of type I muscle fibers compared with those from the sedentary group (Supplemental Table 2 and ref. 27). As expected, muscle tissue from the “active” group exhibited higher slow-twitch gene (MYH7 and MYH7B) expression compared with that from the sedentary control group (Figure (Figure7A).7A). Expression levels of ESRRG and miR-499 were also significantly elevated in the “active” group compared with those in the controls (Figure (Figure7A).7A). In addition, there was a significant positive correlation between ESRRG mRNA levels and both MYH7B and MYH7 mRNA levels (Figure (Figure7B).7B). Moreover, ESRRG mRNA levels were positively correlated with miR-499 levels (Figure (Figure7B).7B). However, this correlation was not observed with miR-208B levels (Figure (Figure77B).
The relationship between ESRRG expression and levels of the miRNAs with determinants of muscle endurance (type I fiber percentage, VO2max, and ATPmax) was next assessed. As shown in Figure Figure7C,7C, a strong positive correlation was observed between the expression of miR-499 and type I fiber percentage, ATPmax, and VO2max. ESRRG expression also correlated with type I fiber percentage, ATPmax, and VO2max. In contrast, the levels of PPARD and PPARA mRNA were not different between sedentary and “active” muscle, and neither exhibited a significant correlation with fiber type, ATPmax, or VO2max (Supplemental Figure 7). Taken together, these results strongly suggest that the ERRγ/miR-499 axis is operative in the regulation of the type I muscle program in humans.
Type I muscle fibers are equipped with a high-capacity mitochondrial system and a distinct set of contractile protein isoforms poised for endurance. The circuitry involved in the coordinate control of these seemingly distinct but highly interrelated processes is unknown. Recently, a clue was provided when the nuclear receptors PPARβ/δ and ERRγ, transcriptional regulators of cellular energy metabolism (28), were independently shown to drive an increase in slow oxidative fiber composition and vascularity in mice (14, 22, 29–31). Herein, we show that PPARβ/δ and ERRγ function to activate transcription of the Myh7 and Myh7b genes, increasing the levels of miR-208b and miR-499 and, thereby, triggering a cascade of muscle slow-twitch contractile protein gene expression (19, 20). The related nuclear receptor PPARα suppresses the activating effects of PPARβ/δ/ERRγ on Myh7/miR-208b and Myh7b/miR-499.
Muscle endurance is determined by multiple factors, including capacity for mitochondrial fuel oxidation and ATP synthesis, fiber-type mix, and vascularity (1–3). The inducible transcriptional coactivator PGC-1α was shown previously to coordinately trigger these programs in muscle-specific transgenic mice (13). Thereafter, muscle transgenes for PPARβ/δ and ERRγ, known transcription factor targets of PGC-1, were shown to exhibit a trained muscle phenotype, including increased expression of well-established PPAR/ERR target genes involved in mitochondrial energy transduction and oxidative phosphorylation, together with an increased proportion of type I fibers (14, 16, 22, 29–31). We sought to delineate the regulatory circuitry linking the activation of energy metabolic genes with the fiber-type program by taking advantage of the markedly different muscle phenotypes of the MCK-PPARα and MCK-PPARβ/δ lines. Using a combination of gene expression and miRNA profiling, we found that ERRγ/ERRβ and miR-208b/miR-499 levels were increased in parallel with expression of type I fiber genes in the muscle of MCK-PPARβ/δ mice. In striking contrast, miR-208b/miR-499 levels were suppressed in MCK-PPARα muscle, together with a lack of induction of ERRγ and ERRβ and suppression of the type I program. These results were intriguing given the recent discovery that miR-208b and miR-499 are embedded in slow-twitch MHC genes and serve to activate slow-twitch fiber program by downregulating the expression of transcriptional repressors, including Sox6 and Purb, which, in turn, suppress slow-twitch genes (19, 20, 32–36).
We found that ERRγ serves a critical role in this regulatory network by directly activating transcription of the Myh7 (miR-208b) and Myh7b (miR-499) genes via highly conserved ERR-responsive elements. The expression of ERRγ and the related ERRβ (but not ERRα) is elevated in MCK-PPARβ/δ muscle through mechanisms that remain unknown. Interestingly, the results of our studies using myotubes in culture suggest that activation of the type I fiber program by PPARβ/δ occurs via a ligand-independent mechanism (data not shown). The mouse ERRγ has at least two different promoters. We have found that the activity of both promoters is increased in MCK-PPARβ/δ muscle, with the transcript driven by the downstream promoter exhibiting the greatest increase in MCK-PPARβ/δ muscle (data not shown). Using informatics search approaches, we have not been able to identify conserved PPAR binding motifs (37, 38) in potential regulatory regions in the DNA sequence spanning from approximately –100 kb upstream to approximately 50 kb downstream of the ERRγ downstream promoter transcription initiation site. Thus, we conclude that activation of ERRγ by PPARβ/δ likely occurs via an indirect mechanism. In addition, it is possible that PPARβ/δ and ERRγ interact at other levels, including, but not limited to, cooperating (directly or indirectly) to activate transcription of type I fiber genes. Our results also suggest that the ERRγ/β-driven muscle fiber-type program does not require the transcriptional coactivator PGC-1α, which has been shown to regulate fiber type, likely in response to endurance training (13, 39–43). However, it would seem likely that with certain physiological conditions, such as exercise, induction of PGC-1 could further enhance the mechanism described herein by coactivating PPARβ/δ. Taken together, our results suggest the existence of a regulatory network, as shown in Figure Figure88.
Muscle fiber-type proportion is determined by both fundamental developmental mechanisms and postnatal physiological stimuli, such as exercise training (1–3). The tissue-selective promoters used in the generation of gain-of-function (PPAR transgene) and loss-of-function (Esrrg/Esrrb gene knockout) mouse lines for this study are both active during prenatal development, suggesting that the mechanisms described may be capable of driving fundamental fiber-type determination. However, the results of our CLFS studies in cell culture indicate that this nuclear receptor/miRNA regulatory circuit is inducible. Interestingly, we found that ERRγ is required for the CLFS-triggered induction of this program. In addition, our survey of the human muscle samples also demonstrated that the ERRγ/miR-499 circuit was activated in the “active” group. Specifically, ESRRG and miR-499 levels were higher in muscle samples obtained from trained “active” individuals compared with those of sedentary individuals. We also found that the expression of ESRRG and miR-499 was strongly correlated with fiber-type proportion, expression of MYH7 and MYH7B genes, and measures of enhanced exercise performance (including VO2max). However, we did not see similar correlations with PPARD or PPARA expression in humans. This could relate to species differences. Alternatively, the programs directed by PPARA and PPARD in humans may not be manifest in the “active”-versus-sedentary group comparison, because this pathway is primarily involved in other genetic programs (e.g., fundamental developmental programs). Given that we did not conduct a longitudinal training study in humans or mice, our results do not allow us to determine whether this regulatory pathway is involved in the response to endurance training or determination of fundamental fiber type during development. Obviously, these are not mutually exclusive roles, and future studies will be necessary to further delineate the function of this pathway in response to physiological inputs.
The upstream regulatory mechanisms that link inputs, such as developmental cues or exercise, to the network defined here are unknown. Evidence has emerged that exercise induces a switch in the relative abundance of transcriptional corepressor complexes, such as the nuclear receptor corepressor 1/histone deacetylase (NCoR1/HDAC) (44, 45) complex, and coactivator complexes containing inducible factors, such as PGC-1α (13, 39–43), at the regulatory regions of key genes that control muscle mitochondrial function and fiber type. Interestingly, NCoR1/HDAC– and PGC-1α–containing cofactor complexes are known to corepress or coactivate ERRs (44, 46, 47) and PPARs (44, 47, 48), respectively, thereby suggesting a mechanism whereby the pathways described here could be dynamically modulated. In addition, the transcriptional coregulator MED13 was recently shown to control metabolism downstream of miR-208a in heart, suggesting additional potential control mechanisms (49).
Surprisingly, in contrast to miR-499, miR-208b levels were not higher in the “active” muscle compared with those in control. The reason for this difference compared with the results in the mouse lines is not clear. This could reflect a species-specific posttranscriptional regulatory effect. Indeed, evidence is emerging that RNA processing, including but not limited to alternative splicing and RNA degradation, are highly active and regulated in muscle. It is tempting to speculate that such mechanisms are active in human muscle such that the miR-208b steady-state levels are not increased in humans.
In summary, we have identified a gene regulatory pathway, involving nuclear receptor and miRNA signaling, which is involved in the coordinate control of muscle energy metabolism and fiber type. Increased proportion of type I fibers and enhanced mitochondrial function are linked to improved glucose tolerance and insulin sensitivity (6–9). Conversely, obesity and chronic disease states, such as heart failure, result in detrained muscle, with reduced numbers of oxidative muscle fibers and diminished fuel-burning capacity. Therefore, the regulatory network described here shows promise as a candidate target for new therapeutic approaches aimed at coordinately increasing muscle type I fibers and energy metabolic capacity.
Esrrg- and Esrrb-floxed (ERRγ/ERRβL2/L2) mice were generated at the Mouse Clinical Institute in Strasbourg according to a strategy previously described (44) and back-crossed to the C57BL/6JBomTac background for 10 generations. To generate mice with skeletal muscle–specific deletions of the ERRγ/ERRβ alleles (herein referred to as ERRβ/γ dmKO mice), ERRγ/ERRβL2/L2 mice were crossed to human skeletal actin–Cre (HSA-Cre) mice. PPARα-null (Ppara–/–) mice in the C57BL/6J background were purchased from The Jackson Laboratory (stock no. 008154). High-expressing (HE) MCK-PPAR mice have been previously described (16, 17). C3B6F1 MCK-miR-499 mice (19) were bred with MCK-PPARα mice to generate the MCK-PPARα/miR-499 double-transgenic mice. The MCK-PPARα mice are in a C57BL/6J pure strain and MCK-PPARβ/δ mice are in a hybrid B6/CBA background, with the following specific exceptions: hybrid MCK-PPAR mouse lines were used in Figure Figure33 (C3/B6) and Supplemental Table 1 (B6/CBA). NTG littermate controls were used in all cases. Of note, fiber-type analyses confirmed that the fiber-type switch phenotype was similar in pure B6 mice compared with that in the hybrid MCK-PPAR mice (data not shown).
Details on subject characteristics and procedures have been described previously (27) and are provided in Supplemental Table 2. Briefly, mitochondrial capacity, as measured by ATPmax, was determined on a 3T GE Signa MNS magnet (GE) using a 4- or 6-cm 31P-tuned surface coil positioned over the distal vastus lateralis. For maximum aerobic capacity (VO2max), cardiorespiratory testing was conducted in the Exercise Testing Core, using a standardized graded exercise testing protocol on a stationary bicycle ergometer (Lode Excalibur). After an overnight fast and local anesthesia, skeletal muscle was collected from the vastus lateralis muscle, cleaned, and mounted for fiber typing as described previously (27) or flash frozen in liquid nitrogen for RNA isolation.
Endurance exercise was determined as described previously (16) with the following exception. Fed mice were run for 10 minutes at 10 meters per minute followed by a constant speed of 20 meters per minute until exhaustion. For assessment of ERRβ/γ dmKO mouse running capacity, mice were run for 45 minutes at 15 meters per minute at 5% incline, followed by an increase of 2 meters per minute every 15 minutes until exhaustion (defined as remaining on the shock grid for more than 1 minute).
Muscle tissue was frozen in isopentane that had been cooled in liquid nitrogen. MHC ATPase and immunofluorescence stains were conducted as previously described (39, 50). MHC ATPase stains were performed at pH 4.31. Under these acidic conditions, MHC2 isoforms are inactivated while MHC1 is still functional, resulting in addition of black dye to MHC1-positive muscle fibers. For immunofluorescence stains, the fibers were quantified (MHC1, green; MHC2a, blue; MHC2x, black [unstained]; MHC2b, red) and expressed as relative numbers of the different fiber types.
Total RNA isolated from soleus muscles of 3-month-old MCK-PPARα (HE) or MCK-PPARβ/δ (HE) mice and NTG littermates using the RNAzol method (Tel-Test) was used for the gene expression array. TaqMan Rodent microRNA Arrays v2.0 (A and B) (Applied Biosystems) were performed by the Sanford-Burnham Medical Research Institute Analytical Genomics Core. For miRNA cDNA synthesis, 1 μg RNA was reverse transcribed using the miRNA Reverse Transcription Kit in combination with the stem-loop Megaplex Primer Pool (Applied Biosystems) in a total of 7.5 μl volume. Quantitative real-time PCR was performed using the Applied Biosystems 7900HT system and a TaqMan Universal PCR Master Mix, with 6 μl cDNA input per plate using the following conditions: 10 minutes at 94.5°C followed by 40 cycles of 97°C for 30 seconds and 59.7°C for 1 minute. Real-Time StatMiner Software from Integromics was used for the data analysis, and mouse snoRNA202 was used as endogenous control for data correction. Ct values greater than 30 in both NTG and MCK-PPAR mice were excluded. Fold change was calculated by the 2–ΔΔCt method using averaged values from 3 trials. The relative miRNA level was normalized to NTG control. A moderated t test was performed to identify significance, as defined by the following criteria: P value less than 0.01 and fold change greater than 2 (either direction).
Real-time quantitative RT-PCR was performed as described previously (16). Specific oligonucleotide primers for target gene sequences are listed in Supplemental Table 3. Arbitrary units of target mRNA were corrected to expression of 36b4 or GAPDH. The gene expression array and miRNA array data have been deposited in NCBI’s Gene Expression Omnibus (GEO) and are accessible through GEO accession numbers GSE5777, GSE29055, and GSE36498 (miRNA array).
Total RNA was isolated from mouse muscle or primary myotubes using the RNAzol method (Tel-Test) for miRNA assay. Total RNA from human muscle biopsy specimens was extracted using the RNeasy Mini Kit and the miRNeasy Mini Kit (Qiagen). TaqMan methods were used to assess miRNA expression. Briefly, 10 ng RNA (for skeletal muscle) or 50 ng RNA (for primary myotubes) was reverse transcribed to cDNA with the TaqMan MicroRNA Reverse Transcription Kit and the TaqMan MicroRNA Assays specific for each miRNA (Assay ID: hsa-miR-208b, 2290; mmu-miR-499, 1352; has-miR-499, 1045) or for the internal controls (Assay ID: snoRNA202, 1232; RNU48, 1006) (Applied Biosystems). Thermal cycling was performed on an Applied Biosystems 7900HT system. The relative miRNA level was corrected to snoRNA202 or RNU48.
Antibodies directed against MHC1 (BA-D5), MHC2b (BF-F3), and MHC2a (SC-71) were purchased from the Developmental Studies Hybridoma Bank; anti-ERRγ antibody was provided by Ronald Evans (Salk Institute for Biological Studies, San Diego, California, USA); anti-GAPDH antibody was purchased from Abcam; antibody directed against S6 ribosomal protein (S6RP) was purchased from Cell Signaling Technology. Western immunoblotting studies were performed as previously described (16).
Primary muscle cells were isolated from skeletal muscles as previously described (16). C2C12 cells were cultured at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum. For differentiation, cells were washed with PBS and refed with 2% horse serum/DMEM differentiation medium and refed daily. Primary myoblasts were infected with an adenovirus overexpressing GFP, PPARβ/δ, PPARα, ERRγ, GFP shRNA, or PPARβ/δ shRNA as previously described (16, 51). Twelve hours after infection, cells were induced to differentiation for 3 days.
CLFS was applied to primary mouse myotubes with a S88X stimulator (Grass Technologies). This instrument provides a positive phase followed by a negative phase of identical duration and voltage. During the 1-s trains, a 200-ms pulse stimulus with 2.5 V and a frequency of 2 Hz was applied. The contractions of the myotubes were verified by examination under microscope. Primary myotubes were stimulated for 4 hour per day for 4 days.
For inhibition of miR-208b and/or miR-499, validated miRCURY LNA microRNA Power Inhibitors (has-miR-499-5p: ACATCACTGCAAGTCTT; has-miR-208b: ACAAACCTTTTGTTCGTCTT; and a negative control A: GTGTAACACGTCTATACGCCCA) were purchased from Exiqon and transfected into primary myoblasts at a final concentration of 20 to 50 nM using HiPerFect Transfection Reagent (Qiagen) according to the manufacturer’s instructions. Twelve hours after transfection, cells were induced to differentiation for 3 days.
siRNAs (ON-TARGET plus SMARTpool, Dharmacon) targeting mouse Esrrg were transfected into primary myoblasts at a final concentration of 20 nM using HiPerFect Transfection Reagent (Qiagen) according to the manufacturer’s instructions. Cells were then differentiated for 3 days prior to harvest.
pSG5, pSG5-ERRβ, pSG5-ERRγ, pBOS, pBOS-PPARα, pcDNA3.1, and pcDNA3.1-PGC-1α vectors have been described previously (16, 52). The 1.0-kb mouse Myh7b promoter-reporter (32) vector was provided by Leslie Leinwand (University of Colorado, Boulder, Colorado, USA). The rat Myh7 promoter constructs (53) were provided by Kenneth Baldwin (University of California, Irvine, California, USA). Site-directed mutagenesis was performed using the QuikChange Kit (Stratagene) according to the manufacturer’s protocol, using complementary oligonucleotides as follows (with mutated nucleotides shown in bold and with lowercase letters): 5′-GCTGTTGTCAgatctAGCAAAGGAG (Myh7b ERRmut). Transient transfections in primary myoblasts or C2C12 cells were performed using Attractene Transfection Reagent (Qiagen) as per the manufacturer’s protocol. Luciferase assay was performed using Dual-Glo (Promega) according to the manufacturer’s recommendations. All transfection data are presented as the mean ± SEM for at least 3 separate transfection experiments performed in triplicate.
ChIP assays were performed as previously described (16). Briefly, primary myotubes were cross-linked with 1% formaldehyde (10 minutes), and cells were collected and lysed. Chromatin fragmentation was performed by sonication using a Bioruptor (Diagenode). Proteins were immunoprecipitated by using anti-ERRγ or IgG control (Sigma-Aldrich). Following reversal of crosslinking, DNA was isolated (QIAquick PCR Purification Kit, Qiagen). QPCR products were assessed and measured using the Stratagene MX3005P detection system. Quantitative analysis was performed by the standard curve method. Specific oligonucleotide primers for target regions are listed in Supplemental Table 4.
All mouse and cell studies were analyzed by 2-tailed Student’s t test or 1-way ANOVA coupled to a Fisher’s least significant difference post-hoc test when more than 2 groups were compared. Data represent the mean ± SEM, with a statistically significant difference defined as P < 0.05. Statistical analyses in human studies were performed using JMP 9.0.0 (SAS Institute Inc.), and values are presented as mean ± SEM. Gene expression levels in human studies were analyzed using the Spearman correlation or Pearson correlation test. Significant differences were defined as P < 0.05.
After signing the informed written consent approved by the Pennington Biomedical Research Center (PBRC) ethical review board, patients were enrolled the in clinical trial performed in Baton Rouge, Louisiana, USA, at the PBRC. Volunteers qualified for the study (ACTIV; Clinicaltrials.gov ID NCT00401791) if they ranged in age from 20 to 40 years, had a BMI of 20 to 30 kg/m2, were nondiabetic, took no medications, and were otherwise healthy. Animal studies were conducted in strict accordance with the NIH guidelines for humane treatment of animals and approved by the IACUC committees at Sanford-Burnham Medical Research Institute at Lake Nona and The Scripps Research Institute at La Jolla.
This work was supported by NIH grants RO1DK045416 (to D.P. Kelly), R01AR41928 (to K.E. Conley), R01AG030226 (to S.R. Smith), and R01DK095686 (to A. Kralli) and a postdoctoral fellowship (11POST7420013) from the American Heart Association (to Z. Gan). E.N. Olson was supported by grants from the Robert A. Welch Foundation, the American Heart Association, Jon Holden DeHaan Foundation, and the Fondation Leducq TransAtlantic Network of Excellence in Cardiovascular Research Program. J. Auwerx was supported by grants from the ERC, the Ecole Polytechnique Fédérale de Lausanne, and the Swiss National Science Foundation. S.R. Smith was supported by Novartis Clinical Innovation Fund. Special thanks to Leslie Leinwand (University of Colorado) for providing the 1.0-kb mouse Myh7b promoter-reporter vector, Ronald Evans (Salk Institute for Biological Studies) for the anti-ERRγ antibody, Sudip Bajpeyi (PBRC) for the initial characterization of the human muscle samples, and the Analytical Genomics Core and the Histology Core at Sanford-Burnham Medical Research Institute at Lake Nona. We are grateful for Lorenzo Thomas for assistance with manuscript preparation, Xiaoman Li (University of Central Florida) for help with bioinformatics analyses, and Lauren Ashley Gabriel for assistance with animal studies.
Conflict of interest: Daniel P. Kelly is on scientific advisory boards for Pfizer and Lilly and has received research funds from Takeda Pharmaceuticals. Eric N. Olson holds equity in miRagen Therapeutics, which is developing miRNA-based therapies for heart and muscle disease. Steven R. Smith has received research funds from Novartis Clinical Innovation Fund and Takeda Pharmaceuticals.
Note regarding evaluation of this manuscript: Manuscripts authored by scientists associated with Duke University, The University of North Carolina at Chapel Hill, Duke-NUS, and the Sanford-Burnham Medical Research Institute are handled not by members of the editorial board but rather by the science editors, who consult with selected external editors and reviewers.
Citation for this article: J Clin Invest. 2013;123(6):2564–2575. doi:10.1172/JCI67652.